Acute promyelocytic leukemia (APL) molecular diagnosis and minimal residual disease (MRD) monitoring are currently based on bcr1, bcr2 or bcr3 fusion transcript detection, depending on the DNA breakpoint21,22. Here, BCRP3 is linked to acute promyelocytic leukemia.